Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Summary
Ocrelizumab is a humanized monoclonal antibody targeting cluster of differentiation 20 (CD20)-positive B cells which play a key role in MS.1,2
Clinical Trials
Ocrelizumab
| NCT ID | Study Phase | Enrollment Status | Study Title | |
|---|---|---|---|---|
| NCT07667322 | Phase I | Recruiting | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | View details |
| NCT07074886 | Phase II | Recruiting | A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | View details |
| NCT07609719 | Phase IV | Recruiting | A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | View details |
| NCT03523858 | Phase III | Active, not recruiting | A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis | View details |
| NCT04035005 | Phase III | Active, not recruiting | A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | View details |
| NCT05269004 | Phase III | Active, not recruiting | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | View details |
| NCT04544436 | Phase III | Active, not recruiting | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | View details |
| NCT04548999 | Phase III | Active, not recruiting | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | View details |
| NCT04075266 | Phase II | Active, not recruiting | A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | View details |
| NCT05123703 | Phase III | Active, not recruiting | A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | View details |
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT
-
CD20
Cluster of differentiation 20 -
MS
Multiple Sclerosis -
PPMS
Primary progressive multiple sclerosis -
RMS
Relapsing multiple sclerosis